The test doesn't detect concussions and the approval won't immediately change how patients with suspected concussions are treated. But it allows Banyan Biomarkers to commercialize its test, giving the company an early lead in the race to find a way…Original Article
You may also like
Gone in a Puff of Smoke? FDA’s Proposed Rule on...
FDA Appears to Be Granting Zombie Rare Pediatric...
HPM’s Larry Houck Presenting at WCF Opioid and...
Get Up To Speed on Medicare Inflation Rebates: HPM...
Into the Ashtray: FDA’s Previous Proposal to Ban...
Small Change: FDA’s Final Predetermined Change...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.